Biodexa Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Biodexa Pharmaceticals
BDRX Stock   4.27  0.57  11.78%   
Biodexa Pharmaceticals financial statements provide useful quarterly and yearly information to potential Biodexa Pharmaceticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Biodexa Pharmaceticals financial statements helps investors assess Biodexa Pharmaceticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Biodexa Pharmaceticals' valuation are summarized below:
Gross Profit
145 K
Market Capitalization
2.9 M
Enterprise Value Revenue
4.6966
Revenue
83 K
Earnings Share
(74.69)
We have found one hundred twenty available fundamental signals for Biodexa Pharmaceticals, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Biodexa Pharmaceticals prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 1.8 M in 2025. Enterprise Value is likely to rise to about (4.2 M) in 2025

Biodexa Pharmaceticals Total Revenue

625,746

Check Biodexa Pharmaceticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biodexa Pharmaceticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 242 K, Selling General Administrative of 3.9 M or Other Operating Expenses of 11.7 M, as well as many indicators such as Price To Sales Ratio of 0.0119, Dividend Yield of 0.0 or PTB Ratio of 0.001. Biodexa financial statements analysis is a perfect complement when working with Biodexa Pharmaceticals Valuation or Volatility modules.
  
Check out the analysis of Biodexa Pharmaceticals Correlation against competitors.
For more information on how to buy Biodexa Stock please use our How to Invest in Biodexa Pharmaceticals guide.

Biodexa Pharmaceticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets9 M9.5 M21.1 M
Pretty Stable
Other Current Liabilities2.5 M4.5 M3.3 M
Pretty Stable
Total Current Liabilities3.8 M5 M4.8 M
Pretty Stable
Property Plant And Equipment Net488.2 K513.9 K1.3 M
Pretty Stable
Accounts Payable268.5 K282.6 K1.1 M
Pretty Stable
Cash8 M5.4 M8.3 M
Very volatile
Non Current Assets Total3 M3.2 M10.7 M
Pretty Stable
Other Assets3.2 M3 M1.4 M
Slightly volatile
Cash And Short Term Investments8 M5.4 M8.3 M
Very volatile
Non Current Liabilities Total252.2 K265.5 K2.2 M
Slightly volatile
Other Current Assets1.3 M953.1 K1.5 M
Pretty Stable
Other Stockholder Equity59.2 M99.7 M51.8 M
Slightly volatile
Total Liabilities5.8 M5.3 M7.1 M
Slightly volatile
Total Current Assets10 M6.3 M10.5 M
Very volatile
Intangible Assets2.5 M2.6 M6.2 M
Pretty Stable
Short and Long Term Debt Total396.7 K417.6 K2.2 M
Slightly volatile
Net Receivables455.7 K633.6 K489.7 K
Very volatile
Liabilities And Stockholders Equity9 M9.5 M21.6 M
Pretty Stable
Accumulated Other Comprehensive Income53.6 M70.8 M41.3 M
Slightly volatile
Short Term Debt144.5 K152.1 K508.2 K
Slightly volatile
Common Stock1.4 M1.4 M331.4 K
Slightly volatile
Net Tangible Assets8.9 M12 M8.2 M
Slightly volatile
Common Stock Shares Outstanding38.1 K36.3 K9.8 K
Slightly volatile
Capital Lease Obligations504.3 K417.6 K898.7 K
Slightly volatile
Net Invested Capital7.9 M4.2 M17.6 M
Slightly volatile
Property Plant And Equipment Gross2.8 M2.1 M5.6 M
Slightly volatile
Capital Stock1.4 M1.4 M343.3 K
Slightly volatile
Net Working Capital1.2 M1.3 M6.5 M
Slightly volatile
Property Plant Equipment1 M1 M1.7 M
Slightly volatile
Other Liabilities40 K45 K49.1 K
Slightly volatile
Current Deferred Revenue1.1 M1.1 M265.7 K
Slightly volatile

Biodexa Pharmaceticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization242 K254.7 K764.9 K
Very volatile
Selling General Administrative3.9 M5 M3.5 M
Slightly volatile
Other Operating Expenses11.7 M9.7 M9.8 M
Slightly volatile
Research Development7.6 M4.7 M6.2 M
Slightly volatile
Total Operating Expenses5 M3.9 M5.7 M
Very volatile
Total Revenue625.7 K342.9 K625.9 K
Pretty Stable
Selling And Marketing Expenses5.1 K5.4 K290.7 K
Slightly volatile
Cost Of Revenue4.7 M3.7 M3.9 M
Slightly volatile
Interest Expense43 K36.9 K76.4 K
Slightly volatile
Reconciled Depreciation242 K254.7 K974.5 K
Slightly volatile

Biodexa Pharmaceticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation242 K254.7 K783.8 K
Very volatile
Capital Expenditures380.6 K236.7 K425.3 K
Pretty Stable
End Period Cash Flow8 M5.4 M8.3 M
Very volatile
Begin Period Cash Flow2.4 M2.6 M7.4 M
Very volatile
Issuance Of Capital Stock7 M9.4 M11.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.01190.01260.7903
Slightly volatile
PTB Ratio0.0010.0010.0347
Very volatile
Days Sales Outstanding814776381
Pretty Stable
Book Value Per Share1621705.5 K
Slightly volatile
Capex To Depreciation0.861.070.8586
Slightly volatile
PB Ratio0.0010.0010.0347
Very volatile
Payables Turnover9.3511.667.8999
Slightly volatile
Sales General And Administrative To Revenue9.313.119.5129
Pretty Stable
Research And Ddevelopement To Revenue16.5712.2815.779
Pretty Stable
Capex To Revenue1.180.790.9221
Pretty Stable
Cash Per Share2072173.2 K
Slightly volatile
Days Payables Outstanding30.7932.414.5 K
Slightly volatile
Income Quality0.921.110.8611
Pretty Stable
Intangibles To Total Assets0.260.250.24
Pretty Stable
Current Ratio1.381.452.5746
Very volatile
Tangible Book Value Per Share60.0863.242.1 K
Slightly volatile
Receivables Turnover0.460.495.2765
Pretty Stable
Graham Number94499418.5 K
Slightly volatile
Shareholders Equity Per Share1621705.5 K
Slightly volatile
Debt To Equity0.110.09921.1752
Slightly volatile
Capex Per Share9.19.5893.4527
Slightly volatile
Revenue Per Share13.1813.87197
Slightly volatile
Interest Debt Per Share17.4718.391.7 K
Slightly volatile
Debt To Assets0.04810.05060.2127
Slightly volatile
Operating Cycle564703506
Pretty Stable
Price Book Value Ratio0.0010.0010.0347
Very volatile
Days Of Payables Outstanding30.7932.414.5 K
Slightly volatile
Ebt Per Ebit1.241.071.1339
Very volatile
Total Debt To Capitalization0.180.10.2802
Slightly volatile
Debt Equity Ratio0.110.09921.1752
Slightly volatile
Quick Ratio1.521.62.6138
Very volatile
Net Income Per E B T0.70.850.8627
Pretty Stable
Cash Ratio1.171.232.056
Very volatile
Days Of Sales Outstanding814776381
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.171.191.0753
Pretty Stable
Price To Book Ratio0.0010.0010.0347
Very volatile
Fixed Asset Turnover0.420.60.4674
Slightly volatile
Debt Ratio0.04810.05060.2127
Slightly volatile
Price Sales Ratio0.01190.01260.7903
Slightly volatile
Asset Turnover0.03310.03250.0379
Slightly volatile
Price Fair Value0.0010.0010.0347
Very volatile

Biodexa Pharmaceticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.8 M1.9 M192.1 M
Slightly volatile

Biodexa Fundamental Market Drivers

Cash And Short Term Investments6 M

Biodexa Upcoming Events

26th of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Biodexa Pharmaceticals Financial Statements

Biodexa Pharmaceticals investors use historical fundamental indicators, such as Biodexa Pharmaceticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Biodexa Pharmaceticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.1 M1.1 M
Total Revenue342.9 K625.7 K
Cost Of Revenue3.7 M4.7 M
Stock Based Compensation To Revenue 0.07  0.07 
Sales General And Administrative To Revenue 13.11  9.30 
Research And Ddevelopement To Revenue 12.28  16.57 
Capex To Revenue 0.79  1.18 
Revenue Per Share 13.87  13.18 
Ebit Per Revenue(18.93)(19.88)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CSXCSX Corporation
ETONEton Pharmaceuticals
ALLTAllot Communications

Additional Tools for Biodexa Stock Analysis

When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY